X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (154) 154
humans (151) 151
oncology (129) 129
male (128) 128
female (125) 125
aged (115) 115
middle aged (108) 108
lung neoplasms - drug therapy (79) 79
adult (64) 64
carcinoma, non-small-cell lung - drug therapy (61) 61
lung neoplasms - pathology (60) 60
chemotherapy (58) 58
aged, 80 and over (53) 53
gefitinib (50) 50
respiratory system (46) 46
treatment outcome (46) 46
cancer (43) 43
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
lung cancer, non-small cell (42) 42
lung neoplasms - genetics (42) 42
lung neoplasms - mortality (36) 36
non-small cell lung cancer (36) 36
lung cancer (35) 35
mutation (35) 35
carcinoma, non-small-cell lung - pathology (34) 34
neoplasm staging (34) 34
receptor, epidermal growth factor - genetics (32) 32
retrospective studies (31) 31
carcinoma, non-small-cell lung - genetics (30) 30
carcinoma, non-small-cell lung - mortality (30) 30
care and treatment (30) 30
erlotinib (29) 29
disease-free survival (26) 26
prognosis (25) 25
docetaxel (24) 24
protein kinase inhibitors - therapeutic use (24) 24
japan (23) 23
adenocarcinoma - drug therapy (21) 21
follow-up studies (21) 21
antineoplastic agents - therapeutic use (20) 20
therapy (20) 20
cisplatin (19) 19
egfr mutation (19) 19
lung cancer, small cell (19) 19
research (19) 19
acquired-resistance (18) 18
medicine & public health (18) 18
quinazolines - therapeutic use (18) 18
survival (18) 18
survival rate (18) 18
trial (18) 18
adenocarcinoma (17) 17
cancer research (17) 17
carboplatin (17) 17
chemistry (17) 17
clinical trials (17) 17
heterocyclic compounds (17) 17
metallurgy (17) 17
open-label (17) 17
organic chemistry (17) 17
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
hematology, oncology and palliative medicine (16) 16
pulmonary/respiratory (16) 16
survival analysis (16) 16
epidermal growth factor (15) 15
multicenter (15) 15
non-small-cell lung cancer (15) 15
patients (15) 15
receptor, epidermal growth factor - antagonists & inhibitors (15) 15
1st-line treatment (14) 14
adenocarcinoma - genetics (14) 14
adenocarcinoma - pathology (14) 14
analysis (14) 14
metastasis (14) 14
mutation - genetics (14) 14
bevacizumab (13) 13
cancer therapies (13) 13
carboplatin - administration & dosage (13) 13
growth-factor receptor (13) 13
respiratory tract diseases (13) 13
tumors (13) 13
tyrosine (13) 13
antineoplastic agents - adverse effects (12) 12
biopsy (12) 12
cell lung-cancer (12) 12
drug administration schedule (12) 12
epidermal growth factor receptors (12) 12
erlotinib hydrochloride (12) 12
genetic aspects (12) 12
mutations (12) 12
safety (12) 12
t790m (12) 12
antineoplastic agents - administration & dosage (11) 11
cisplatin - administration & dosage (11) 11
efficacy (11) 11
kaplan-meier estimate (11) 11
lung neoplasms - therapy (11) 11
medicine, general & internal (11) 11
original (11) 11
pharmacology & pharmacy (11) 11
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 2, pp. 121 - 128
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2010, Volume 28, Issue 5, pp. 753 - 760
Journal Article
Oncotarget, ISSN 1949-2553, 06/2018, Volume 9, Issue 47, pp. 28292 - 28293
Journal Article
Cancer Science, ISSN 1347-9032, 02/2016, Volume 107, Issue 2, pp. 162 - 167
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2018, Volume 36, Issue 10, pp. 1050 - 1050
Journal Article
Cancer Science, ISSN 1347-9032, 04/2018, Volume 109, Issue 4, pp. 1177 - 1184
Osimertinib is a potent, irreversible epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI ) selective for EGFR ‑ TKI sensitizing ( EGFR... 
cytology | T790M | epidermal growth factor receptor | non‐small cell lung cancer | osimertinib | non-small cell lung cancer | 1ST-LINE TREATMENT | ACQUIRED-RESISTANCE | FOLLOW-UP | EGFR MUTATION | OPEN-LABEL | CHEMOTHERAPY | CLINICAL-PRACTICE GUIDELINES | RANDOMIZED PHASE-3 TRIAL | SPECIMENS | ONCOLOGY | ERLOTINIB | Lung Neoplasms - genetics | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - genetics | Humans | Middle Aged | ErbB Receptors - genetics | Male | Mutation - genetics | Piperazines - pharmacology | Disease-Free Survival | Asian Continental Ancestry Group | Mutation - drug effects | Aged, 80 and over | Adult | Female | Aged | Antineoplastic Agents - pharmacology | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Medical research | Care and treatment | Development and progression | Lung cancer, Small cell | Lung cancer, Non-small cell | Complications and side effects | Epidermal growth factor | Analysis | Medicine, Experimental | Skin | Diagnosis | Cancer | Plasma | Peptides | Epidermal growth factor receptors | Research funding | Lung cancer | Cytology | Stockholders | Diarrhea | Cancer therapies | Patients | Disease control | Studies | Acids | Cellular biology | Biopsy | Mutation | Protein-tyrosine kinase | Tumors | Index Medicus | Original
Journal Article
British Journal of Cancer, ISSN 0007-0920, 01/2018, Volume 118, Issue 1, pp. 32 - 37
Background: Osimertinib demonstrated promising efficacy for refractory leptomeningeal metastases (LM) in preclinical data and a clinical study at 160 mg, but... 
T790M | leptomeningeal metastases | cerebrospinal fluid | osimertinib | SYSTEM | GEFITINIB | EFFICACY | ACQUIRED-RESISTANCE | TYROSINE KINASE INHIBITORS | GROWTH-FACTOR RECEPTOR | THERAPY | ONCOLOGY | BRAIN METASTASES | MUTATIONS | ERLOTINIB | Piperazines - administration & dosage | ErbB Receptors - cerebrospinal fluid | Lung Neoplasms - drug therapy | Prospective Studies | Humans | Middle Aged | ErbB Receptors - genetics | Carcinoma, Non-Small-Cell Lung - cerebrospinal fluid | Lung Diseases, Interstitial - chemically induced | Protein Kinase Inhibitors - adverse effects | Lung Neoplasms - cerebrospinal fluid | Meningeal Neoplasms - drug therapy | Protein Kinase Inhibitors - cerebrospinal fluid | Lung Diseases, Interstitial - epidemiology | Lung Neoplasms - genetics | Meningeal Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Treatment Outcome | Piperazines - adverse effects | Protein Kinase Inhibitors - administration & dosage | Pilot Projects | Meningeal Neoplasms - cerebrospinal fluid | Piperazines - cerebrospinal fluid | Progression-Free Survival | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Meningeal Neoplasms - secondary | Tyrosine | Epidermal growth factor receptors | Lung diseases | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Cerebrospinal fluid | Metastasis | Patients | Metastases | Epidermal growth factor | Meninges | Lesions | Protein-tyrosine kinase | Cancer | Index Medicus | Clinical Study
Journal Article
Lung Cancer, ISSN 0169-5002, 2016, Volume 101, pp. 1 - 8
Journal Article
by Garassino, Marina Chiara and Cho, Byoung-Chul and Kim, Dong-Wan and Kim, Joo-Hang and Kim, Sang-We and Kim, Young-Chul and Mazières, Julien and Vansteenkiste, Johan and Lena, Hervé and Corral Jaime, Jesus and Gray, Jhanelle E and Powderly, John and Chouaid, Christos and Bidoli, Paolo and Wheatley-Price, Paul and Park, Keunchil and Soo, Ross A and Huang, Yifan and Wadsworth, Catherine and Dennis, Phillip A and Rizvi, Naiyer A and Paz-Ares Rodriguez, Luis and Novello, Silvia and Hiret, Sandrine and Schmid, Peter and Laack, Eckart and Califano, Raffaele and Maemondo, Makoto and Chaft, Jamie and Vicente Baz, David and Berghmans, Thierry and Surmont, Veerle and Reck, Martin and Han, Ji-Youn and Holgado Martin, Esther and Belda Iniesta, Cristobal and Oe, Yuichiro and Chella, Antonio and Chopra, Akhil and Robinet, Gilles and Soto Parra, Hector and Thomas, Michael and Cheema, Parneet and Katakami, Nobuyuki and Su, Wu-Chou and Wolf, Juergen and Lee, Jong-Seok and Saka, Hideo and Milella, Michele and Ramos Garcia, Inmaculada and Sibille, Anne and Yokoi, Takashi and Kang, Eun Joo and Atagi, Shinji and Spaeth-Schwalbe, Ernst and Nishio, Makoto and Imamura, Fumio and Gabrail, Nashat and Veillon, Remi and Derijcke, Sofie and Maeda, Tadashi and Zylla, Dylan and Kubiak, Kendra and Santoro, Armando and Uy, Ma. Noemi and Lucien Geater, Sarayut and Italiano, Antoine and Kowalski, Dariusz and Barlesi, Fabrice and Chen, Yuh-Min and Spigel, David and Chewaskulyong, Busyamas and Garcia Gomez, Ramon and Alvarez Alvarez, Rosa and Yang, Chih-Hsin and Hsia, Te-Chun and Denis, Fabrice and Sakai, Hiroshi and Vincent, Mark and Goto, Koichi and Bosch-Barrera, Joaquim and Weiss, Glen and Canon, Jean-Luc and Scholz, Christian and Aglietta, Massimo and Kemmotsu, Hirotsugu and Azuma, Koichi and Bradbury, Penelope and Feld, Ronald and Chachoua, Abraham and Jassem, Jacek and Juergens, Rosalyn and Palmero Sanchez, Ramon and Malcolm, Albert and Vrindavanam, Nandagopal and Kubota, Kaoru and Waller, Cornelius and Waterhouse, David and Coudert, Bruno and Mark, Zsuzsanna and ... and ATLANTIC Investigators
The Lancet Oncology, ISSN 1470-2045, 04/2018, Volume 19, Issue 4, pp. 521 - 536
Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without tyrosine kinase or anaplastic... 
MULTICENTER | METAANALYSIS | NSCLC | ONCOLOGY | RANDOMIZED CONTROLLED-TRIAL | ATEZOLIZUMAB | IMMUNE CHECKPOINT | NIVOLUMAB | MEDI4736 | CLINICAL ACTIVITY | DOCETAXEL | Lung cancer, Non-small cell | Care and treatment | Index Medicus
Journal Article